logo-loader

Open Orphan PLC: 'Rapidly scaling up and building out higher value, longer term contracts'

Published: 08:06 14 May 2020 EDT

 

Proactive Research analyst Emma Ulker says Open Orphan PLC (LON:ORPH) is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services.

She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the full, growing the top line and targeting near term profitability by delivering specialist pharma services across its hVIVO and Venn subsidiaries.

Click here to read Emma Ulker's latest update Open Orphan: Scaling Up, Leveraging Valuable Assets

hVIVO Canary Wharf move to deliver material increase in capacity - Proactive...

Proactive research analyst Daniel Appiah speaks to Thomas Warner at the London studio about his latest report into specialist contract research organisation hVIVO PLC (AIM:HVO). hVIVO is expanding its presence by establishing a cutting-edge facility at the Canary Wharf Life Sciences Hub in...

on 5/9/23